TABLE I.

Effect of omalizumab on PBMC and pDC IFN-α^* secretion^†

Mechanistic parameter		Omalizumab					Placebo
Cell type	Ex vivo stimulus	No.	Pre- randomization, mean (SD)	Post- randomization, mean (SD)	Ratio of geometric means (95% CI)	P value	No.	Pre- randomization, mean (SD)	Post- randomization, mean (SD)	Ratio of geometric means (95% CI)	P value
PBMC	Rhinovirus	64	1365.8 (6.1)	1035.8 (7.0)	0.76 (0.47–1.22)	.25	23	1443.1 (6.3)	764.2 (7.9)	0.53 (0.21–1.32)	.16
	Anti-IgE plus rhinovirus	56	201.7 (6.9)	415.7 (8.2)	2.06 (1.20–3.55)	.01	23	169.7 (5.5)	129.0 (6.4)	0.76 (0.34–1.71)	.49
	Influenza virus	64	7304.7 (2.2)	7301.8 (2.4)	1.00 (0.80–1.24)	>.99	23	6864.2 (3.7)	6371.6 (2.6)	0.93 (0.50–1.74)	.81
	Anti-IgE plus influenza virus	38	4352.1 (2.6)	6814.9 (2.3)	1.57 (1.09–2.25)	.02	10	4043.6 (5.6)	4637.1 (3.9)	1.15 (0.20–6.51)	.86
	Gardiquimod	64	856.4 (3.8)	1167.3 (4.1)	1.36 (1.00–1.87)	.05	23	1314.3 (4.7)	985.4 (3.4)	0.75 (0.49–1.16)	.18
pDC	Rhinovirus	25	125.2 (5.3)	237.5 (7.1)	1.90 (0.83–4.34)	.12	12	216.3 (7.6)	260.4 (8.0)	1.2 (0.26–5.64)	.80
	Anti-IgE plus rhinovirus	14	94.8 (4.4)	393.6 (6.4)	4.15 (1.76–9.77)	.003	7	174.8 (7.2)	277.7 (6.7)	1.59 (0.19–13.14)	.61
	Influenza	25	236.6 (3.7)	317.5 (3.5)	1.34 (0.87–2.08)	.18	11	171.6 (4.7)	340.2 (3.4)	1.98 (0.84–4.70)	.11
pDC	Gardiquimod	21	936.6 (6.5)	1900.2 (4.7)	2.03 (0.85–4.83)	.10	11	1280.3 (6.6)	1955.4 (2.7)	1.53 (0.33–7.14)	.55

Boldface indicates P < .05.

^*IFN-α concentrations (in picograms per milliliter) measured in supernatants after depicted ex vivo stimulations.

^†Means are geometric means, and SDs are geometric SDs.